1. Generics Bulletin
  2. >>Business
  3. >>Deals

Biocon Pays $3.3bn For Viatris Biosimilars Business

‘Transformational’ Deal Offers Biocon Portfolio, Pipeline And Global Presence

 
• By Dave Wallace

Biocon Biologics will pay up to $3.3bn to acquire the global biosimilars business of Viatris, in a long-rumored deal that will create a vertically-integrated biosimilars giant with annual sales approaching $1bn.

Jigsaw pieces sunset
The deal combines Biocon Biologics with Viatris biosimilars • Source: rangizzz / Alamy Stock Photo

After months of rumors, Biocon has confirmed that its Biocon Biologics unit will acquire the global biosimilars business of Viatris in a deal worth up to $3.3bn.

Both companies’ boards have approved the transaction, which offers India’s Biocon a substantial portfolio and pipeline as well as a direct presence in markets such as the US and Europe, along with Canada, Japan, Australia and New Zealand, creating a “unique global, vertically-integrated biosimilars leader” with annual revenues closing on $1bn

More from Deals

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

More from Business